PHPenelope Hey

Penelope Hey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Penelope Hey has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transjugular intrahepatic portosystemic shunt: patient characteristics and predictors of adverse outcomes from a quaternary referral centre

    by Oliver Nilsen, Nirbaanjot Walia, Ernest Cheung, Jonathan Abdelmalak, Jessica Spurio, Monique Fernandez, Thomas Freeman, Penelope Hey, Karl Vaz, Marie Sinclair, et al.

    Background: Transjugular intrahepatic portosystemic shunt (TIPS) placement remains a key intervention for managing complications of portal hypertension. Regular assessment of patient characteristics and outcomes is required to inform ongoing patient selection. Aim: To describe the characteristics, indications and outcomes of patients undergoing TIPS and to identify risk factors for post‐TIPS hepatic encephalopathy (HE) and mortality. Methods: This was a retrospective study of patients who underwent TIPS between 2011 and 2024 at a quaternary liver transplant centre. Demographics, indications for TIPS and outcomes were collected. Multivariable Cox regression analysis was used to identify predictors of 90‐day HE and mortality post‐ TIPS. Results: In this cohort, TIPS was performed in 143 patients (median age 55 years interquartile range 48–62). Alcohol‐related liver disease ( ARLD ) was the most common aetiology in 57 (40.0%), followed by metabolic dysfunction‐associated steatotic liver disease ( MASLD ) in 26 (18.2%). Indications included ascites and/or hepatic hydrothorax in 76 (53.1%), followed by variceal haemorrhage in 53 (37.1%). Within 90 days, 43.8% developed HE and 18.6% died. Type 2 diabetes mellitus (subdistribution hazard ratio (HR) = 1.99, 95% confidence interval ( CI) : 1.17–3.38, P = 0.012) was independently associated with HE within 90 days of TIPS , while age ( HR = 1.07, 95% CI : 1.02–1.13, P = 0.009), model for end‐stage liver disease ( MELD) ( HR 1.12, 95% CI : 1.05–1.19, P < 0.001) and salvage TIPS for variceal bleeding ( HR = 3.77, 95% CI : 1.40–10.15, P = 0.009) were independently associated with 90‐day mortality. Conclusion: TIPS insertion was most often performed for fluid‐related indications, with ARLD and MASLD being the common underlying aetiologies. Type 2 diabetes predicted HE , whereas age, MELD and salvage TIPS for variceal haemorrhage were associated with increased mortality.

  • Meeting the demand: Incorporating living donor liver transplantation into the deceased donor liver transplantation landscape

    by Karl Vaz, Penelope Hey, Graham Starkey, Therese Bittermann, Maarouf A. Hoteit, Marcos V. Perini, Michael A. Fink, Avik Majumdar, Marie Sinclair, Adam Testro, et al.

    Liver transplantation (LT) has for decades been a well-established treatment for end-stage liver disease and malignancy, becoming the standard of care for select patients with these life-limiting conditions. Due to a limited pool of high-quality deceased donor organs, there is an existing and growing disparity between those in need of and those able to access LT. Living donor liver transplantation (LDLT) has emerged as one way to mitigate this disparity. Despite Australia’s place in history as the first reported LDLT from mother-to-child in 1987, living donation for adults is rare, in part due to perceived lack of need due to the historically low waitlist mortality data. This Perspective reviews the history of LDLT and utilises Australia as a case-study for exploring the necessity for LDLT in existing deceased donor liver transplant programs, the ethical considerations, risks and benefits of the procedure, and the means to implement LDLT.


  • Open Access

    The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus

    by Avik Majumdar, Jacinta Holmes, Stuart K. Roberts, Purnima Bhat, Tim Mitchell, Jeyamani Ramachandran, James O’BEirne, Sarah Walker, Rohit Sawhney, Nishita Jagarlamudi, et al.

    Background: In Australia, chronic liver disease is now the third leading cause of premature death in people aged 50–59 years, and the fourth leading cause in all other 5-year age groups from 35 to 70 years in Australia. A consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis was developed by the Gastroenterological Society of Australia (GESA), the peak national organization for health care professionals and researchers working in gastroenterology and hepatology, to provide contemporary, evidence-based clinical guidelines. A summary of its recommendations is presented here. Methods: The consensus statement was developed in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument and the 2016 National Health and Medical Research Council Standards for Guidelines. A panel of 46 health care professionals with expertise in managing portal hypertension participated in the development of the consensus statement. The consensus development conference method was used to determine consensus for each recommendation, with a hybrid face-to-face and online meeting held in Noosa, Australia, on 3 August 2024, followed by 2 online meetings. Results: A total of 52 recommendations were approved by the consensus development group without dissent across the following domains: (1) diagnosis, risk stratification, and prevention of decompensation; (2) portal hypertension–related bleeding; (3) ascites and renal impairment; (4) hepatic encephalopathy; (5) sarcopenia, nutrition, and frailty; (6) thrombosis in cirrhosis; (7) cardiopulmonary complications; (8) surgery and portal hypertension; and (9) pregnancy and portal hypertension. Discussion: This is the first Australian consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis. The recommendations in this summary document provide standardized clinical guidance with the goal of improving outcomes for patients with cirrhosis and portal hypertension in Australia.


  • Open Access

    Prognostic scores for early mortality following transjugular intrahepatic portosystemic shunt insertion: external validation in a contemporary Australian cohort

    by Nirbaanjot Walia, Oliver Nilsen, Ernest Cheung, Jonathan Abdelmalak, Jessica Spurio, Monique Fernandez, Thomas Freeman, Penelope Hey, Karl Vaz, Marie Sinclair, et al.

    Background: Mortality following transjugular intrahepatic portosystemic shunt (TIPS) placement remains a critical concern. Traditional scoring systems, such as the Model for End‐Stage Liver Disease (MELD) and MELD‐Na, as well as the newer Modified TIPS‐Score (MOTS) and Freiburg Index of Post‐TIPS Survival (FIPS), have shown potential for refining risk stratification. Aims: To externally validate prognostic scores for predicting 30‐ and 90‐day mortality following TIPS. Methods: This retrospective study, conducted at Austin Health, Australia, included 117 patients who underwent TIPS with ≥90 days of follow‐up between 2011 and 2024. Prognostic scores were calculated using pre‐TIPS clinical and laboratory data. Discrimination and calibration were assessed and prognostic accuracy evaluated at established thresholds for MELD ≥ 18, MELD‐Na ≥ 20, MOTS > 1, FIPS ≥ 0.92 and additional scores. Results: TIPS indications included ascites and/or hepatic hydrothorax (56.4%), variceal haemorrhage (34.2%), Budd‐Chiari syndrome (6.0%) and other indications (3.4%). Mortality occurred in 13 (11.1%) and 21 patients (17.9%) by 30 and 90 days respectively. MELD demonstrated the best discrimination for 30‐day mortality (area under the curve (AUC) = 0.82), followed by MOTS (0.80), FIPS (0.76) and MELD‐Na (0.73), with similar trends at 90 days. MOTS was best calibrated, followed by FIPS and MELD. FIPS ≥ 0.92 had excellent specificities (94% and 95%) and negative predictive values (94% and 88%) for 30‐ and 90‐day mortality, marginally outperforming MELD and MOTS. MELD‐Na and other scores performed less well. Conclusion: MOTS, MELD and FIPS demonstrated robust discriminative performance for early post‐TIPS mortality and outperformed other models. Further research is required to establish optimum risk thresholds for these tools and support these findings.


  • Reply: Targeted enteral feeding for malnutrition in liver transplant candidates

    by Brooke Chapman, Darren Wong, Marie Sinclair, Penelope Hey, Ryma Terbah, Paul Gow, Avik Majumdar, Adam Testro

  • Reversing malnutrition and low muscle strength with targeted enteral feeding in patients awaiting liver transplant: A randomized controlled trial

    by Brooke Chapman, Darren Wong, Marie Sinclair, Penelope Hey, Ryma Terbah, Paul Gow, Avik Majumdar, Adam Testro

    Background and Aims: Most patients with decompensated cirrhosis fail to meet their nutrition targets. The impact of nasogastric feeding (NGF) on malnutrition in cirrhosis remains unknown. This study aims to assess the impact of pretransplant NGF on pre–liver transplant and post–liver transplant outcomes. Approach and Results: This single-center, prospective randomized controlled trial of 55 patients with severe malnutrition and low handgrip strength (HGS) compared a standard high-energy high-protein diet to diet plus supplemental nocturnal NGF while awaiting transplant. The primary outcome was a change in HGS. The median age was 58.5 years (IQR: 51.1–64), median MELD was 24 (20–28.5), and 32 (58%) patients were male. The median duration of NGF was 63.0 days (34.5–127), following which time the median between-group difference in HGS was 3.6 kg (95% CI: 1.7–5.2, pp100% of their measured nutritional requirements. Posttransplant clinical outcomes were similar between groups. Conclusions: Targeted enteral feeding before liver transplant improves HGS, anthropometry, and immune function in severely malnourished patients with cirrhosis. These findings provide a strong rationale for early consideration of NGF to reverse malnutrition and improve muscle strength. Appropriately powered studies should explore whether NGF can also impact clinically relevant outcomes including pretransplant and posttransplant mortality.


  • Open Access

    Branched‐chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: results of a randomised controlled trial

    by Penelope Hey, Rudolf Hoermann, Marie Sinclair, Brooke Chapman, Adam Testro, Ross Apostolov, Peter Angus, Paul Gow

    Summary: Background: Sarcopenia is associated with adverse outcomes in cirrhosis. Branched‐chain amino acids (BCAA) target several pathways that lead to muscle loss in this population.Aims: We aimed to evaluate the impact of BCAA supplementation on sarcopenia measures in patients with cirrhosis.Methods: We conducted a 12‐month double‐blinded, randomised, controlled trial of BCAA supplementation (30 g daily) compared to an equicaloric, equi‐nitrogenous whey protein in volunteers with cirrhosis and reduced muscle strength. The primary endpoint was an increase in grip strength and upper limb lean mass measured on DEXA. Mean‐adjusted differences (MAD, 95% CI) between groups at 6 and 12 months are reported as treatment effect using a linear mixed model for repeated measures.Results: A total of 150 volunteers entered the trial (74 BCAA, 76 control), with a median age of 58 years [IQR 48; 63] and MELD of 14 [12; 17]. At 12 months, 57% in the BCAA arm and 61% in the control arm met the primary endpoint (p = 0.80). No significant between‐group difference was found in grip strength (MAD ‐0.15 kg [−0.37; 0.06], p = 0.29) or upper limb lean mass (1.7 kg [−0.2; 3.6], p = 0.22) at 12 months. No significant differences in other body composition parameters, physical performance, frailty, rates of hospitalisation or mortality were found between the BCAA and the control group. Fatigue improved across the entire cohort, without significant between‐group differences. 15% of volunteers reported side effects, with distaste higher in the BCAA arm (p = 0.045).Conclusion: BCAA supplementation did not improve measures of muscle strength, mass or performance or physical frailty compared to a whey protein supplement in a randomised controlled setting. ACTRN12618000802202.


  • Transjugular intrahepatic portosystemic shunt insertion improves muscle mass but not muscle function or frailty measures

    by Penelope Hey, Brooke Chapman, Darren Wong, Paul Gow, Adam Testro, Ryma Terbah, Marie Sinclair

    Introduction: Sarcopenia in cirrhosis is associated with poor outcomes. While transjugular intrahepatic portosystemic shunt (TIPS) insertion improves radiological measures of muscle mass, its impact on muscle function, performance and frailty has not been evaluated. Methods: Patients with cirrhosis referred for TIPS were prospectively recruited and followed for 6 months. L3 CT scans were used to calculate skeletal muscle and adipose tissue parameters. Handgrip strength, Liver Frailty Index and short physical performance battery were serially monitored. Dietary intake, insulin resistance, insulin-like growth factor (IGF)-1, and immune function using QuantiFERON Monitor (QFM) were measured. Results: Twelve patients completed the study with a mean age of 58 ± 9 years and model for end-stage liver disease score of 16 ± 5. At 6 months post-TIPS, skeletal muscle area increased from 139.33 cm2 ± 22.72 to 154.64 ± 27.42 (P = 0.012). Significant increases were observed in the subcutaneous fat area (P = 0.0076) and intermuscular adipose tissue (P = 0.041), but not muscle attenuation or visceral fat. Despite marked changes in muscle mass, no improvements were observed in handgrip strength, frailty, or physical performance. At 6 months post-TIPS, IGF-1 (P = 0.0076) and QFM (P = 0.006) increased compared to baseline. Nutritional intake, hepatic encephalopathy measures, insulin resistance and liver biochemistry were not significantly impacted. Conclusion: Muscle mass increased following TIPS insertion as did IGF-1, a known driver of muscle anabolism. The lack of improvement in muscle function was unexpected and may relate to impairment in muscle quality and the effects of hyperammonaemia on muscle contractile function. Improvements in QFM, a marker of immune function, may suggest a reduction in infection susceptibility in this at-risk population and requires further evaluation.


  • Open Access

    The sex‐specific prognostic utility of sarcopenia in cirrhosis

    by Ryan Lowe, Penelope Hey, Marie Sinclair

    Sarcopenia is an increasingly recognized complication of cirrhosis that is associated with morbidity and mortality. Differences in the prevalence and prognosis of sarcopenia between men and women have been reported in other patient groups, but there is insufficient understanding of how sex impacts the prognostic value of sarcopenia in cirrhosis. A search of MEDLINE and Embase was conducted from earliest entries to April 2021. Studies were included if they examined sex‐stratified mortality impact of reduced muscle function or mass in outpatient populations with cirrhosis. We identified 700 studies of which 6 were deemed relevant for inclusion in this narrative review. Studies of interest were heterogeneous, precluding pooling of data and making interpretation of the literature challenging. Muscle mass was assessed in five studies (n = 2566, 1730 men, 836 women) and was reduced in 36–50% of men and 24–43% of women. All five studies found that reduced muscle mass determined by computed tomography, dual‐energy X‐ray absorptiometry, and bioelectrical impedance analysis was associated with increased mortality in men. Of these, two studies identified a corresponding relationship in women; reduced muscle mass defined by computed tomography was associated with increased mortality [hazard ratio (HR) 2.82, P = 0.001], while increasing muscle mass by bioelectrical impedance analysis likewise conferred a survival benefit (HR 0.45, P = 0.0016). Only one study assessed the relationship of muscle function with sex‐stratified mortality (n = 1405, 827 men, 578 women), concluding that reduced muscle function predicted mortality in both men and women (HR 1.65, P < 0.001 and HR 1.54, P < 0.001, respectively). Reduced muscle mass in cirrhosis is consistently associated with mortality in men, but lack of sex‐stratification of mortality analyses limits the ability to make strong conclusions about the impact of sarcopenia specifically in women, with even fewer data available for analysing muscle function. Improved understanding of the sex‐specific impacts of sarcopenia may help address patient deterioration and mortality while awaiting liver transplantation and allow for early intervention to mitigate mortality risk. Large, multicentre studies with adequate female participation and sex‐stratified mortality analyses are warranted.